Why It's Fierce: Effective treatments for central nervous system disorders remain few and far between. We think Aderis has a few winners in its portfolio. The company tailors small molecule to regulate dopamine and other proteins. Aderis has four products in Phase II or Phase III studies including a transdermal patch for Parkinson's disease and a treatment for restless legs syndrome. We're not the only ones betting on Aderis. Germany's Schwarz Pharma, King Pharmaceuticals, and Fujisawa Healthcare have pledged capital and marketing support for the company's lead products.
What to look for in 2003: Look for results from a pivotal study in Parkinson's disease this year.